275 related articles for article (PubMed ID: 26383592)
21. Psoralen-ultraviolet A-induced erythema: sensitivity correlates with the concentrations of psoralen in suction blister fluid.
Yeo UC; Shin JH; Yang JM; Park KB; Kim MM; Bok HS; Lee ES
Br J Dermatol; 2000 Apr; 142(4):733-9. PubMed ID: 10792224
[TBL] [Abstract][Full Text] [Related]
22. Time course of skin photosensitivity following trimethylpsoralen bath PUVA.
Man I; Wainwright NJ; Gibbs NK; Ferguson J
Photodermatol Photoimmunol Photomed; 2000 Oct; 16(5):211-5. PubMed ID: 11068860
[TBL] [Abstract][Full Text] [Related]
23. Assessment of minimal phototoxic dose following 8-methoxypsoralen bath: maximal reaction on average after 5 days.
Behrens-Williams S; Gruss C; Grundmann-Kollmann M; Peter RU; Kerscher M
Br J Dermatol; 2000 Jan; 142(1):112-5. PubMed ID: 10651704
[TBL] [Abstract][Full Text] [Related]
24. Phototesting in bath-PUVA: marked reduction of 8-methoxypsoralen (8-MOP) activity within one hour after an 8-MOP bath.
Schempp CM; Schöpf E; Simon JC
Photodermatol Photoimmunol Photomed; 1996 Jun; 12(3):100-2. PubMed ID: 8956358
[TBL] [Abstract][Full Text] [Related]
25. The effect of methoxsalen dose on ultraviolet-A-induced erythema.
Ibbotson SH; Dawe RS; Farr PM
J Invest Dermatol; 2001 May; 116(5):813-5. PubMed ID: 11348476
[TBL] [Abstract][Full Text] [Related]
26. Comparative studies on the tolerance to photoinduced cutaneous inflammatory reactions by psoralen and rose bengal.
Kumar JR; Haberman HF; Ranadive NS
J Photochem Photobiol B; 1997 Feb; 37(3):245-53. PubMed ID: 9085568
[TBL] [Abstract][Full Text] [Related]
27. Bath-5-methoxypsoralen-UVA therapy for psoriasis.
Calzavara-Pinton PG; Zane C; Carlino A; De Panfilis G
J Am Acad Dermatol; 1997 Jun; 36(6 Pt 1):945-9. PubMed ID: 9204060
[TBL] [Abstract][Full Text] [Related]
28. Glutathione S-transferase genotype is associated with sensitivity to psoralen-ultraviolet A photochemotherapy.
Ibbotson SH; Dawe RS; Dinkova-Kostova AT; Weidlich S; Farr PM; Ferguson J; Wolf CR; Smith G
Br J Dermatol; 2012 Feb; 166(2):380-8. PubMed ID: 21967523
[TBL] [Abstract][Full Text] [Related]
29. The relationship between plasma psoralen concentration and psoralen-UVA erythema.
Mclelland J; Fisher C; Farr PM; Diffey BL; Cox NH
Br J Dermatol; 1991 Jun; 124(6):585-90. PubMed ID: 2064944
[TBL] [Abstract][Full Text] [Related]
30. PUVA-gel vs. PUVA-bath therapy for severe recalcitrant palmoplantar dermatoses. A randomized, single-blinded prospective study.
Schiener R; Gottlöber P; Müller B; Williams S; Pillekamp H; Peter RU; Kerscher M
Photodermatol Photoimmunol Photomed; 2005 Apr; 21(2):62-7. PubMed ID: 15752122
[TBL] [Abstract][Full Text] [Related]
31. Bath PUVA and psoriasis: is a milder treatment a worse treatment?
Delrosso G; Bornacina C; Farinelli P; Bellinzona F; Leigheb G; Colombo E
Dermatology; 2008; 216(3):191-3. PubMed ID: 18182808
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides.
Wackernagel A; Hofer A; Legat F; Kerl H; Wolf P
Br J Dermatol; 2006 Mar; 154(3):519-23. PubMed ID: 16445785
[TBL] [Abstract][Full Text] [Related]
33. Can the immersion time of PUVA bath therapy be shortened?
Schiener R; Behrens-Williams SC; Pillekamp H; Kaskel P; Peter RU; Kerscher M
Acta Derm Venereol; 2002; 82(1):18-20. PubMed ID: 12013191
[TBL] [Abstract][Full Text] [Related]
34. The time-course of psoralen ultraviolet A (PUVA) erythema.
Ibbotson SH; Farr PM
J Invest Dermatol; 1999 Sep; 113(3):346-50. PubMed ID: 10469332
[TBL] [Abstract][Full Text] [Related]
35. Erythemal and therapeutic response of psoriasis to PUVA using high-dose UVA.
Speight EL; Farr PM
Br J Dermatol; 1994 Nov; 131(5):667-72. PubMed ID: 7999598
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
Whittaker S; Ortiz P; Dummer R; Ranki A; Hasan B; Meulemans B; Gellrich S; Knobler R; Stadler R; Karrasch M
Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
[TBL] [Abstract][Full Text] [Related]
37. Cancer incidence among Finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA.
Hannuksela-Svahn A; Pukkala E; Koulu L; Jansén CT; Karvonen J
J Am Acad Dermatol; 1999 May; 40(5 Pt 1):694-6. PubMed ID: 10321595
[TBL] [Abstract][Full Text] [Related]
38. Minimum erythema dose determination in individuals of skin type V and VI with diffuse reflectance spectroscopy.
Kollias N; Baqer A; Sadiq I
Photodermatol Photoimmunol Photomed; 1994 Dec; 10(6):249-54. PubMed ID: 7727281
[TBL] [Abstract][Full Text] [Related]
39. Paired comparison of bathwater versus oral delivery of 8-methoxypsoralen in psoralen plus ultraviolet: A therapy for chronic palmoplantar psoriasis.
Hofer A; Fink-Puches R; Kerl H; Quehenberger F; Wolf P
Photodermatol Photoimmunol Photomed; 2006 Feb; 22(1):1-5. PubMed ID: 16436174
[TBL] [Abstract][Full Text] [Related]
40. Concentration-dependent phototoxicity in trimethylpsoralen bath psoralen ultraviolet A.
Snellman E; Rantanen T
Br J Dermatol; 2001 Mar; 144(3):490-4. PubMed ID: 11260004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
